MPD: Measures involving fluoxetine

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Project1170:1	Project1170	body weight	fluoxetine	body weight at 4-6 wks of age [g] bw_1 121657 group: control fluoxetine	inbred	6	m	4-6wks	N=10	2023

Project1170:3	Project1170	body weight	fluoxetine	body weight at 6-8 wks of age [g] bw_2 121659 group: control fluoxetine	inbred	6	m	6-8wks	N=10	2023

Project1170:5	Project1170	body weight	fluoxetine	body weight at 7-9 wks of age [g] bw_3 121661 group: control fluoxetine	inbred	6	m	7-9wks	N=10	2023

Project1170:7	Project1170	body weight	fluoxetine	body weight at 10-12 wks of age [g] bw_4 121663 group: control fluoxetine	inbred	6	m	10-12wks	N=10	2023

Project1170:9	Project1170	body weight	fluoxetine	body weight at 11-13 wks of age [g] bw_5 121665 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:11	Project1170	body weight	fluoxetine	body weight at time of grip strength test [g] bw_grip 121667 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:13	Project1170	grip strength	fluoxetine	grip strength forepaws, trial 1 [g] forepaw_T1 121669 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:15	Project1170	grip strength	fluoxetine	grip strength forepaws, trial 2 [g] forepaw_T2 121671 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:17	Project1170	grip strength	fluoxetine	grip strength forepaws, trial 3 [g] forepaw_T3 121673 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:19	Project1170	grip strength	fluoxetine	grip strength forepaws, average of all trials [g] forepaw_avg 121675 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:21	Project1170	grip strength	fluoxetine	grip strength forepaws, average of all trials adjusted for body weight [g] forepaw_avg_adj 121677 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:23	Project1170	grip strength	fluoxetine	grip strength all paws, trial 1 [g] all_paw_T1 121679 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:25	Project1170	grip strength	fluoxetine	grip strength all paws, trial 2 [g] all_paw_T2 121681 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:27	Project1170	grip strength	fluoxetine	grip strength all paws, trial 3 [g] all_paw_T3 121683 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:29	Project1170	grip strength	fluoxetine	grip strength all paws, average of all trials [g] all_paw_avg 121685 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:31	Project1170	grip strength	fluoxetine	grip strength all paws, average of all trials adjusted for body weight [g] all_paw_avg_adj 121687 group: control fluoxetine	inbred	6	m	8-9wks	N=10	2023

Project1170:37	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 1 [s] high_mobile_dur_1 121693 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:39	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 2 [s] high_mobile_dur_2 121695 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:41	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 3 [s] high_mobile_dur_3 121697 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:43	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 4 [s] high_mobile_dur_4 121699 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:45	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 5 [s] high_mobile_dur_5 121701 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:47	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 6 [s] high_mobile_dur_6 121703 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:49	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, min 7 [s] high_mobile_dur_7 121705 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:51	Project1170	tail suspension test	fluoxetine	duration mouse was highly mobile, total over 7 min [s] high_mobile_dur_tot 121707 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:53	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 1 [%] high_mobile_pct_1 121709 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:55	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 2 [%] high_mobile_pct_2 121711 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:57	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 3 [%] high_mobile_pct_3 121713 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:59	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 4 [%] high_mobile_pct_4 121715 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:61	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 5 [%] high_mobile_pct_5 121717 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:63	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 6 [%] high_mobile_pct_6 121719 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:65	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, min 7 [%] high_mobile_pct_7 121721 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:67	Project1170	tail suspension test	fluoxetine	percentage of time mouse was highly mobile, average over 7 min [%] high_mobile_pct_avg 121723 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:69	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 1 [s] mobile_dur_1 121725 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:71	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 2 [s] mobile_dur2 121727 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:73	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 3 [s] mobile_dur_3 121729 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:75	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 4 [s] mobile_dur_4 121731 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:77	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 5 [s] mobile_dur_5 121733 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:79	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 6 [s] mobile_dur_6 121735 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:81	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, min 7 [s] mobile_dur_7 121737 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:83	Project1170	tail suspension test	fluoxetine	duration mouse was mobile, total over 7 min [s] mobile_dur_tot 121739 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:85	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 1 [%] mobile_pct_1 121741 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:87	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 2 [%] mobile_pct_2 121743 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:89	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 3 [%] mobile_pct_3 121745 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:91	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 4 [%] mobile_pct_4 121747 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:93	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 5 [%] mobile_pct_5 121749 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:95	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 6 [%] mobile_pct_6 121751 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:97	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, min 7 [%] mobile_pct_7 121753 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:99	Project1170	tail suspension test	fluoxetine	percentage of time mouse was mobile, average over 7 min [%] mobile_pct_avg 121755 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:101	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 1 [s] immobile_dur_1 121757 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:103	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 2 [s] immobile_dur_2 121759 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:105	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 3 [s] immobile_dur_3 121761 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:107	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 4 [s] immobile_dur_4 121763 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:109	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 5 [s] immobile_dur_5 121765 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:111	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 6 [s] immobile_dur_6 121767 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:113	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, min 7 [s] immobile_dur_7 121769 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:115	Project1170	tail suspension test	fluoxetine	duration mouse was immobile, total over 7 min [s] immobile_dur_tot 121771 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:117	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 1 [%] immobile_pct_1 121773 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:119	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 2 [%] immobile_pct_2 121775 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:121	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 3 [%] immobile_pct_3 121777 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:123	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 4 [%] immobile_pct_4 121779 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:125	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 5 [%] immobile_pct_5 121781 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:127	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 6 [%] immobile_pct_6 121783 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:129	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, min 7 [%] immobile_pct_7 121785 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:131	Project1170	tail suspension test	fluoxetine	percentage of time mouse was immobile, average over 7 min [%] immobile_pct_avg 121787 group: control fluoxetine	inbred	6	m	10-12wks	N=9	2023

Project1170:133	Project1170	open field test	fluoxetine	total distance traveled, first 5 min [cm] distance_tot_1 121789 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:135	Project1170	open field test	fluoxetine	total distance traveled, second 5 min [cm] distance_tot_2 121791 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:137	Project1170	open field test	fluoxetine	total distance traveled, third 5 min [cm] distance_tot_3 121793 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:139	Project1170	open field test	fluoxetine	total distance traveled, fourth 5 min [cm] distance_tot_4 121795 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:141	Project1170	open field test	fluoxetine	time spent in periphery, first 5 min [s] margin_time_1 121797 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:143	Project1170	open field test	fluoxetine	time spent in periphery, second 5 min [s] margin_time_2 121799 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:145	Project1170	open field test	fluoxetine	time spent in periphery, third 5 min [s] margin_time_3 121801 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:147	Project1170	open field test	fluoxetine	time spent in periphery, fourth 5 min [s] margin_time_4 121803 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:149	Project1170	open field test	fluoxetine	distance traveled in periphery, first 5 min [cm] margin_dist_1 121805 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:151	Project1170	open field test	fluoxetine	distance traveled in periphery, second 5 min [cm] margin_dist_2 121807 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:153	Project1170	open field test	fluoxetine	distance traveled in periphery, third 5 min [cm] margin_dist_3 121809 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:155	Project1170	open field test	fluoxetine	distance traveled in periphery, fourth 5 min [cm] margin_dist_4 121811 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:157	Project1170	open field test	fluoxetine	time spent in center, first 5 min [s] center_time_1 121813 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:159	Project1170	open field test	fluoxetine	time spent in center, second 5 min [s] center_time_2 121815 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:161	Project1170	open field test	fluoxetine	time spent in center, third 5 min [s] center_time_3 121817 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:163	Project1170	open field test	fluoxetine	time spent in center, fourth 5 min [s] center_time_4 121819 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:165	Project1170	open field test	fluoxetine	distance traveled in center, first 5 min [cm] center_dist_1 121821 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:167	Project1170	open field test	fluoxetine	distance traveled in center, second 5 min [cm] center_dist_2 121823 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:169	Project1170	open field test	fluoxetine	distance traveled in center, third 5 min [cm] center_dist_3 121825 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:171	Project1170	open field test	fluoxetine	distance traveled in center, fourth 5 min [cm] center_dist_4 121827 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:173	Project1170	open field test	fluoxetine	time spent vertical, first 5 min [s] vert_time_1 121829 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:175	Project1170	open field test	fluoxetine	time spent vertical, second 5 min [s] vert_time_2 121831 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:177	Project1170	open field test	fluoxetine	time spent vertical, third 5 min [s] vert_time_3 121833 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:179	Project1170	open field test	fluoxetine	time spent vertical, fourth 5 min [s] vert_time_4 121835 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:181	Project1170	open field test	fluoxetine	number of vertical episodes, first 5 min [n] vert_count_1 121837 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:183	Project1170	open field test	fluoxetine	number of vertical episodes, second 5 min [n] vert_count_2 121839 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:185	Project1170	open field test	fluoxetine	number of vertical episodes, third 5 min [n] vert_count_3 121841 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:187	Project1170	open field test	fluoxetine	number of vertical episodes, fourth 5 min [n] vert_count_4 121843 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:189	Project1170	open field test	fluoxetine	time spent resting, first 5 min [s] rest_time_1 121845 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:191	Project1170	open field test	fluoxetine	time spent resting, second 5 min [s] rest_time_2 121847 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:193	Project1170	open field test	fluoxetine	time spent resting, third 5 min [s] rest_time_3 121849 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:195	Project1170	open field test	fluoxetine	time spent resting, fourth 5 min [s] rest_time_4 121851 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:197	Project1170	open field test	fluoxetine	number of rest episodes, first 5 min [n] rest_count_1 121853 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:199	Project1170	open field test	fluoxetine	number of rest episodes, second 5 min [n] rest_count_2 121855 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:201	Project1170	open field test	fluoxetine	number of rest episodes, third 5 min [n] rest_count_3 121857 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:203	Project1170	open field test	fluoxetine	number of rest episodes, fourth 5 min [n] rest_count_4 121859 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:205	Project1170	open field test	fluoxetine	time spent moving, first 5 min [s] move_time_1 121861 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:207	Project1170	open field test	fluoxetine	time spent moving, second 5 min [s] move_time_2 121863 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:209	Project1170	open field test	fluoxetine	time spent moving, third 5 min [s] move_time_3 121865 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:211	Project1170	open field test	fluoxetine	time spent moving, fourth 5 min [s] move_time_4 121867 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:213	Project1170	open field test	fluoxetine	number of moving episodes, first 5 min [n] move_count_1 121869 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:215	Project1170	open field test	fluoxetine	number of moving episodes, second 5 min [n] move_count_2 121871 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:217	Project1170	open field test	fluoxetine	number of moving episodes, third 5 min [n] move_count_3 121873 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:219	Project1170	open field test	fluoxetine	number of moving episodes, fourth 5 min [n] move_count_4 121875 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:221	Project1170	open field test	fluoxetine	time spent in stereotypic movement, first 5 min [s] stereo_time_1 121877 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:223	Project1170	open field test	fluoxetine	time spent in stereotypic movement, second 5 min [s] stereo_time_2 121879 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:225	Project1170	open field test	fluoxetine	time spent in stereotypic movement, third 5 min [s] stereo_time_3 121881 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:227	Project1170	open field test	fluoxetine	time spent in stereotypic movement, fourth 5 min [s] stereo_time_4 121883 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:229	Project1170	open field test	fluoxetine	number of stereotypic movements, first 5 min [n] stereo_count_1 121885 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:231	Project1170	open field test	fluoxetine	number of stereotypic movements, second 5 min [n] stereo_count_2 121887 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:233	Project1170	open field test	fluoxetine	number of stereotypic movements, third 5 min [n] stereo_count_3 121889 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:235	Project1170	open field test	fluoxetine	number of stereotypic movements, fourth 5 min [n] stereo_count_4 121891 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:237	Project1170	open field test	fluoxetine	number of clockwise movements, first 5 min [n] clockwise_1 121893 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:239	Project1170	open field test	fluoxetine	number of clockwise movements, second 5 min [n] clockwise_2 121895 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:241	Project1170	open field test	fluoxetine	number of clockwise movements, third 5 min [n] clockwise_3 121897 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:243	Project1170	open field test	fluoxetine	number of clockwise movements, fourth 5 min [n] clockwise_4 121899 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:245	Project1170	open field test	fluoxetine	number of counter-clockwise movements, first 5 min [n] c_clockwise_1 121901 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:247	Project1170	open field test	fluoxetine	number of counter-clockwise movements, second 5 min [n] c_clockwise_2 121903 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:249	Project1170	open field test	fluoxetine	number of counter-clockwise movements, third 5 min [n] c_clockwise_3 121905 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Project1170:251	Project1170	open field test	fluoxetine	number of counter-clockwise movements, fourth 5 min [n] c_clockwise_4 121907 group: control fluoxetine	inbred	6	m	11-13wks	N=10	2023

Wiltshire2:1	Wiltshire2	tail suspension test	fluoxetine	TST duration of immobility [%] TST 38001 control fluoxetine	inbred	30	m	9-10wks	N=10	2011

Wiltshire2:3	Wiltshire2	open field test	fluoxetine	OFT center avoidance, thigmotaxis, 10 min test [%] OFT_thig 38003 control fluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire2:5	Wiltshire2	open field test	fluoxetine	OFT distance traveled, 10 min test [cm] OFT_dist 38005 control fluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire2:7	Wiltshire2	drug and metabolite quantification	fluoxetine	drug and metabolite concentration [ng/mL] fluoxetine 38007 fluoxetine norfluoxetine	inbred	30	m	10-11wks	N=11	2011

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:22	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:25	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:37	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:40	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:43	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:46	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:52	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:55	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:58	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:67	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:73	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Project1170

body weight

fluoxetine

body weight at 4-6 wks of age [g] bw_1 121657 group: control fluoxetine

inbred

6

m

4-6wks

N=10

2023

Project1170

body weight

fluoxetine

body weight at 6-8 wks of age [g] bw_2 121659 group: control fluoxetine

inbred

6

m

6-8wks

N=10

2023

Project1170

body weight

fluoxetine

body weight at 7-9 wks of age [g] bw_3 121661 group: control fluoxetine

inbred

6

m

7-9wks

N=10

2023

Project1170

body weight

fluoxetine

body weight at 10-12 wks of age [g] bw_4 121663 group: control fluoxetine

inbred

6

m

10-12wks

N=10

2023

Project1170

body weight

fluoxetine

body weight at 11-13 wks of age [g] bw_5 121665 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

body weight

fluoxetine

body weight at time of grip strength test [g] bw_grip 121667 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength forepaws, trial 1 [g] forepaw_T1 121669 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength forepaws, trial 2 [g] forepaw_T2 121671 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength forepaws, trial 3 [g] forepaw_T3 121673 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength forepaws, average of all trials [g] forepaw_avg 121675 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength forepaws, average of all trials adjusted for body weight [g] forepaw_avg_adj 121677 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength all paws, trial 1 [g] all_paw_T1 121679 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength all paws, trial 2 [g] all_paw_T2 121681 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength all paws, trial 3 [g] all_paw_T3 121683 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength all paws, average of all trials [g] all_paw_avg 121685 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

grip strength

fluoxetine

grip strength all paws, average of all trials adjusted for body weight [g] all_paw_avg_adj 121687 group: control fluoxetine

inbred

6

m

8-9wks

N=10

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 1 [s] high_mobile_dur_1 121693 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 2 [s] high_mobile_dur_2 121695 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 3 [s] high_mobile_dur_3 121697 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 4 [s] high_mobile_dur_4 121699 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 5 [s] high_mobile_dur_5 121701 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 6 [s] high_mobile_dur_6 121703 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, min 7 [s] high_mobile_dur_7 121705 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was highly mobile, total over 7 min [s] high_mobile_dur_tot 121707 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 1 [%] high_mobile_pct_1 121709 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 2 [%] high_mobile_pct_2 121711 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 3 [%] high_mobile_pct_3 121713 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 4 [%] high_mobile_pct_4 121715 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 5 [%] high_mobile_pct_5 121717 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 6 [%] high_mobile_pct_6 121719 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, min 7 [%] high_mobile_pct_7 121721 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was highly mobile, average over 7 min [%] high_mobile_pct_avg 121723 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 1 [s] mobile_dur_1 121725 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 2 [s] mobile_dur2 121727 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 3 [s] mobile_dur_3 121729 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 4 [s] mobile_dur_4 121731 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 5 [s] mobile_dur_5 121733 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 6 [s] mobile_dur_6 121735 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, min 7 [s] mobile_dur_7 121737 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was mobile, total over 7 min [s] mobile_dur_tot 121739 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 1 [%] mobile_pct_1 121741 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 2 [%] mobile_pct_2 121743 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 3 [%] mobile_pct_3 121745 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 4 [%] mobile_pct_4 121747 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 5 [%] mobile_pct_5 121749 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 6 [%] mobile_pct_6 121751 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, min 7 [%] mobile_pct_7 121753 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was mobile, average over 7 min [%] mobile_pct_avg 121755 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 1 [s] immobile_dur_1 121757 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 2 [s] immobile_dur_2 121759 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 3 [s] immobile_dur_3 121761 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 4 [s] immobile_dur_4 121763 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 5 [s] immobile_dur_5 121765 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 6 [s] immobile_dur_6 121767 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, min 7 [s] immobile_dur_7 121769 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

duration mouse was immobile, total over 7 min [s] immobile_dur_tot 121771 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 1 [%] immobile_pct_1 121773 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 2 [%] immobile_pct_2 121775 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 3 [%] immobile_pct_3 121777 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 4 [%] immobile_pct_4 121779 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 5 [%] immobile_pct_5 121781 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 6 [%] immobile_pct_6 121783 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, min 7 [%] immobile_pct_7 121785 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

tail suspension test

fluoxetine

percentage of time mouse was immobile, average over 7 min [%] immobile_pct_avg 121787 group: control fluoxetine

inbred

6

m

10-12wks

N=9

2023

Project1170

open field test

fluoxetine

total distance traveled, first 5 min [cm] distance_tot_1 121789 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

total distance traveled, second 5 min [cm] distance_tot_2 121791 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

total distance traveled, third 5 min [cm] distance_tot_3 121793 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

total distance traveled, fourth 5 min [cm] distance_tot_4 121795 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in periphery, first 5 min [s] margin_time_1 121797 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in periphery, second 5 min [s] margin_time_2 121799 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in periphery, third 5 min [s] margin_time_3 121801 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in periphery, fourth 5 min [s] margin_time_4 121803 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in periphery, first 5 min [cm] margin_dist_1 121805 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in periphery, second 5 min [cm] margin_dist_2 121807 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in periphery, third 5 min [cm] margin_dist_3 121809 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in periphery, fourth 5 min [cm] margin_dist_4 121811 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in center, first 5 min [s] center_time_1 121813 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in center, second 5 min [s] center_time_2 121815 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in center, third 5 min [s] center_time_3 121817 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in center, fourth 5 min [s] center_time_4 121819 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in center, first 5 min [cm] center_dist_1 121821 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in center, second 5 min [cm] center_dist_2 121823 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in center, third 5 min [cm] center_dist_3 121825 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

distance traveled in center, fourth 5 min [cm] center_dist_4 121827 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent vertical, first 5 min [s] vert_time_1 121829 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent vertical, second 5 min [s] vert_time_2 121831 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent vertical, third 5 min [s] vert_time_3 121833 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent vertical, fourth 5 min [s] vert_time_4 121835 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of vertical episodes, first 5 min [n] vert_count_1 121837 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of vertical episodes, second 5 min [n] vert_count_2 121839 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of vertical episodes, third 5 min [n] vert_count_3 121841 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of vertical episodes, fourth 5 min [n] vert_count_4 121843 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent resting, first 5 min [s] rest_time_1 121845 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent resting, second 5 min [s] rest_time_2 121847 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent resting, third 5 min [s] rest_time_3 121849 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent resting, fourth 5 min [s] rest_time_4 121851 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of rest episodes, first 5 min [n] rest_count_1 121853 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of rest episodes, second 5 min [n] rest_count_2 121855 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of rest episodes, third 5 min [n] rest_count_3 121857 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of rest episodes, fourth 5 min [n] rest_count_4 121859 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent moving, first 5 min [s] move_time_1 121861 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent moving, second 5 min [s] move_time_2 121863 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent moving, third 5 min [s] move_time_3 121865 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent moving, fourth 5 min [s] move_time_4 121867 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of moving episodes, first 5 min [n] move_count_1 121869 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of moving episodes, second 5 min [n] move_count_2 121871 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of moving episodes, third 5 min [n] move_count_3 121873 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of moving episodes, fourth 5 min [n] move_count_4 121875 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in stereotypic movement, first 5 min [s] stereo_time_1 121877 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in stereotypic movement, second 5 min [s] stereo_time_2 121879 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in stereotypic movement, third 5 min [s] stereo_time_3 121881 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

time spent in stereotypic movement, fourth 5 min [s] stereo_time_4 121883 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of stereotypic movements, first 5 min [n] stereo_count_1 121885 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of stereotypic movements, second 5 min [n] stereo_count_2 121887 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of stereotypic movements, third 5 min [n] stereo_count_3 121889 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of stereotypic movements, fourth 5 min [n] stereo_count_4 121891 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of clockwise movements, first 5 min [n] clockwise_1 121893 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of clockwise movements, second 5 min [n] clockwise_2 121895 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of clockwise movements, third 5 min [n] clockwise_3 121897 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of clockwise movements, fourth 5 min [n] clockwise_4 121899 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of counter-clockwise movements, first 5 min [n] c_clockwise_1 121901 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of counter-clockwise movements, second 5 min [n] c_clockwise_2 121903 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of counter-clockwise movements, third 5 min [n] c_clockwise_3 121905 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Project1170

open field test

fluoxetine

number of counter-clockwise movements, fourth 5 min [n] c_clockwise_4 121907 group: control fluoxetine

inbred

6

m

11-13wks

N=10

2023

Wiltshire2

tail suspension test

fluoxetine

TST duration of immobility [%] TST 38001 control fluoxetine

inbred

30

m

9-10wks

N=10

2011

Wiltshire2

open field test

fluoxetine

OFT center avoidance, thigmotaxis, 10 min test [%] OFT_thig 38003 control fluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire2

open field test

fluoxetine

OFT distance traveled, 10 min test [cm] OFT_dist 38005 control fluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire2

drug and metabolite quantification

fluoxetine

drug and metabolite concentration [ng/mL] fluoxetine 38007 fluoxetine norfluoxetine

inbred

30

m

10-11wks

N=11

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GAD1 (GAD67), relative fluorescence intensity GAD1 38122 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GAL, relative fluorescence intensity GAL 38125 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GLO1, relative fluorescence intensity GLO1 38137 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GNB1, relative fluorescence intensity GNB1 38140 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GRIN1 (NMDA1), relative fluorescence intensity GRIN1 38143 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GSK3B, relative fluorescence intensity GSK3B 38146 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex HDAC5, relative fluorescence intensity HDAC5 38152 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex NGF, relative fluorescence intensity NGF 38155 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex NPY, relative fluorescence intensity NPY 38158 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PPP1R1B, relative fluorescence intensity PPP1R1B 38167 control fluoxetine

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex S100B, relative fluorescence intensity S100B 38173 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Wiltshire3

biomarker quantification

fluoxetine

cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index

inbred

30

m

10-11wks

N=3

2011

Filter Table Results